Organization (Hospital)
The Affiliated Hospital of Qingdao University
ClinicalTrials.gov lists The Affiliated Hospital of Qingdao University as lead sponsor of 145 trials. It has 60 active development programs and 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 34 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 42 in 2026 and about 44 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers The Affiliated Hospital of Qingdao University: 145 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (209)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Stomach Neoplasms | 22 |
| Lung Neoplasms | 13 |
| Breast Neoplasms | 11 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Colorectal Neoplasms | 9 |
Showing 5 of 209 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 34 |
| 2025 | 48 |
| 2024 | 29 |
| 2023 | 34 |
| 2022 | 42 |
| 2021 | 32 |
| 2020 | 30 |
| 2019 | 12 |
| 2018 | 22 |
| 2017 | 9 |
Showing 10 of 18 years.
Prediction, not a registry value: median of 35 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 5 months across 53 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (60)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Hyperthermic Intraperitoneal Chemotherapy | Stomach Neoplasms | Phase 3 | 1 |
| Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles | Colorectal Neoplasms | Phase 2 | 1 |
| Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles | Rectal Neoplasms | Phase 2 | 1 |
| Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles | Pathologic Complete Response | Phase 2 | 1 |
| Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles | Disease Progression | Phase 2 | 1 |
Showing 5 of 60 active programs.
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Butorphanol and Propofol | 1 |
| Fluoride Toothpaste | 1 |
| Control toothpaste | 1 |
| Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC) | 1 |
| Clostridium butyricum capsules, Live | 1 |
Showing 5 of 23 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 55% hit target (n=11) | 64% on time (n=11) |
Journals published in (262)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 19 |
| Surgical endoscopy | 15 |
| Journal of Alzheimer's disease : JAD | 14 |
| Annals of surgery | 9 |
| Circulation | 9 |
Showing 5 of 262 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 1 | 2022-11-29 |
Organization relationships (309)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Qilu Hospital of Shandong University | Co sponsors trial with | 12 |
| Tongji Hospital | Co sponsors trial with | 11 |
| First Affiliated Hospital of Zhengzhou University | Co sponsors trial with | 10 |
| Peking Union Medical College Hospital | Co sponsors trial with | 10 |
| The First Hospital of Jilin University | Co sponsors trial with | 10 |
Showing 5 of 309 relationships.
Latest dated events (311)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 311 events.
Biomarker capability evidence (416)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| AIP | Trial collaborator | Named in trial inclusion criteria |
| AIP | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 416 evidence rows.
Biomarkers this organization publishes on (106)
Shown in this order: most publications first.
Showing 5 of 106 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.